Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Neurol Neurosurg Psychiatry. 2012 Sep;83(9):923-6. doi: 10.1136/jnnp-2012-302548. Epub 2012 Jul 11.

Amyloid imaging in Alzheimer's disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography.

Author information

  • 1Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. david.wolk@uphs.upenn.edu

Abstract

BACKGROUND:

Amyloid imaging provides in vivo detection of the fibrillar amyloid-β (Aβ) plaques of Alzheimer's disease (AD). The positron emission tomography (PET) ligand, Pittsburgh Compound-B (PiB-C11), is the most well studied amyloid imaging agent, but the short half-life of carbon-11 limits its clinical viability. Florbetapir-F18 recently demonstrated in vivo correlation with postmortem Aβ histopathology, but has not been directly compared with PiB-C11.

METHODS:

Fourteen cognitively normal adults and 12 AD patients underwent PiB-C11 and florbetapir-F18 PET scans within a 28-day period.

RESULTS:

Both ligands displayed highly significant group discrimination and correlation of regional uptake.

CONCLUSION:

These data support the hypothesis that florbetapir-F18 provides comparable information with PiB-C11.

PMID:
22791901
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Write to the Help Desk